Company: CMND
Filing Date: 2025-01-22
Form Type: 20-F
Source: 0001213900-25-005490
Chunk: 133

Company: Clearmind Medicine Inc.
Filing Date: 2025-01-22
Form: 20-F
Item: Item 4
Chunk 133
---
, we are planning to conduct a Phase I/II single and multiple dose tolerability, safety, and pharmacokinetic clinical
study of CMND-100 in healthy volunteers and AUD subjects.

Competition

The pharmaceutical industry is intensely competitive
and subject to rapid and significant technological change. Our potential competitors include large and experienced companies that have
significant competitive advantages over us, such as greater financial, research and development, manufacturing, personnel and marketing
resources, greater brand recognition, and more experience and expertise in obtaining marketing approvals from the FDA and foreign regulatory
authorities. These companies may develop new drugs to treat the indications that we target or seek to have existing drugs approved for
use in the indications that we target.

These potential competitors may therefore introduce
competing products without our prior knowledge and without our ability to take preemptive measures in anticipation of their commercial
launch. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability
of capital for investment in this industry. Our competitors may succeed in developing, acquiring or licensing on an exclusive basis, products
that are more effective, easier to administer or less costly than our product candidates. is highly competitive, with new approaches and
technologies regularly emerging. We expect to face competition across our current programs and with any future programs we may seek to
develop and/or commercialize from major pharmaceutical, biotechnology, specialty pharmaceutical and generic pharmaceutical companies among
others. Potential competitors also include academic institutions, governmental agencies and other public and private research organizations
that conduct research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and commercialization.

Psychedelic Therapy Competitive Landscape for
AUD

Other than us, more than 45 players from across
the world presently claim to be engaged in the development and evaluation of therapeutic candidates based on a number of psychedelic compounds.

In the mental illnesses segments, we will face
competition from psychedelic companies in general, and also from psychedelic companies that are focusing on alcohol abuse, like Awakn
Life Sciences, B. More Inc. and Journey Colab Corp.

Intellectual Property

Our success depends in large part on our ability
to obtain and maintain protection of intellectual property, particularly patents, in the United States and other countries with respect
to product candidates, uses and other technologies that are important to our business. In addition to patent protection, we also may rely
on trade secrets to protect aspects of our business for which we do not consider patent protection appropriate.

The Company’s intellectual portfolio currently
cons